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                                   INTRODUCTION 
 
                             Rheumatoid Arthritis is the commonest form of chronic 
inflammatory joint disease. It is a symmetrical, non suppurative polyarticular 
disease unique to modern man.1   Rheumatoid arthritis affects the synovial 
joints, but it is not confined to them and  the many visceral manifestations 
have led to the classification of  RA as a systemic  disorder of immunological 
mechanism.1 
                          Rheumatoid arthritis is associated with increased morbidity 
and mortality because of cardiovascular disease , independent of traditional 
risk factors.15  Cardiovascular disease due to accelerated atherosclerosis is a 
leading cause of mortality in rheumatoid arthritis (RA).  Endothelial 
dysfunction often precedes manifest atherosclerosis. Both traditional risk 
factors and inflammation-associated factors are involved in RA-associated 
atherosclerosis. 
                               The contribution of inflammation to atherogenesis is 
supported by epidemiological evidence on the independent predictive value 
of inflammatory markers for subclinical and clinical atherosclerosis and for 
associated CV events. However, the impact of lipids on CV risk in the 
chronic autoimmune inflammatory setting of RA is unclear and the literature 
on lipid profile in patients with RA is contradictory. A number of studies 
 
 
have demonstrated either a proatherogenic or a  favourable lipid profile in 
RA. Growing evidence suggests that patients with active untreated RA have 
reduced total cholesterol (TC), low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol. The conflicting results can be 
attributed to confounding by indication and, possibly, to the effect of 
inflammation and treatment. Comprehensive analyses of trends in lipids both 
before and after RA incidence are lacking and the exact impact of RA onset 
on lipids is unknown. 
                                          Among imaging techniques, the early 
determination of common carotid intima-media thickness (ccIMT), flow-
mediated vasodilation (FMD), and nitroglycerine-mediated vasodilation 
(NMD) may be useful to determine atherosclerosis and endothelial 
dysfunction.  
 
                                          The early diagnosis of endothelial dysfunction and  
atherosclerosis, active  immunosuppressive  treatment,  the use of drugs that  
control atherosclerosis,  changes in sedentary lifestyle, and the close follow-
up of RA patients may help to minimize cardiovascular risk in these 
individuals.  Preventing atherosclerosis and its progression remains a central 
goal in medicine.13 
 
                                        REVIEW OF LITERATURE    
 
 
DEFINITIONS 
RHEUMATOID ARTHRITIS 
                                    Rheumatoid arthritis is a chronic systemic 
inflammatory disease of undetermined etiology involving primarily the 
synovial membranes and articular structures of multiple joints. The disease is 
often progressive and results in pain, stiffness, and swelling of joints. In late 
stages, deformity and ankylosis develop. Rheumatoid arthritis can also cause 
significant extra-articular manifestations most probably related to systemic 
inflammation.19 
PATHOPHYSIOLOGY 
                                     The genetic predisposition and the environmental 
factors,  importantly infections play a major role in the causation of  RA. The 
class II molecule particularly HLA- DR4 is associated with 70% of RA 
patients. The susceptibility to RA is associated with the third hypervariable 
region of the DR β chains from aminoacids 70 through 74. Deficient 
galactosylation of the immunoglobulin G might also be a risk factor for the 
development of RA.  The primary targets of inflammation are synovial 
membranes and articular structures. Other organs are affected as well. 
Inflammation, proliferation, and degeneration typify synovial membrane 
involvement. Joint deformities and disability result from the erosion and 
destruction of synovial membranes and articular surfaces.19                                                   
 
 
                               Factors associated with rheumatoid arthritis include the 
possibility of infectious triggers, genetic predisposition, and autoimmune 
response. CD4+ T cells stimulate the immune cascade leading to cytokine 
production such as tumor necrosis factor alpha (TNF-a) and interleukin-1.19 
EPIDEMIOLOGY                                         
                                 Rheumatoid arthritis occurs throughout the world and in 
all ethnic groups. Its prevalence is approximately 1% of the population. ; 
women are affected approximately three times more than men. The 
prevalence increases with age but the sex difference diminish in old age. The 
onset is more frequent during the fourth and fifth decade of life, with 80% of 
all patients developing the disease between 35 and 50 years of age.20                
CLINICAL FEATURES25 
                      The clinical manifestations include articular and extra 
articular features. The articular manifestation may have an insidious onset in 
55-65 % of patients, acute onset in 8-15% of patients and subacute in 15-20% 
of patients. The unusual pattern of onset may be adult onset Still’s disease or 
polymyalgia rheumatic type.  The  joints  most  commonly  involved  first  
are metacarpophalangeal   joints,    proximal  interphalangeal  joints, 
metatarsophalangeal joints and wrists. The large joints become symptomatic 
after the small joints . 
 
 
                          The extra articular manifestation includes 
subcutaneous nodules, episcleritis, scleritis, myositis, vasculitis, pulmonary 
manifestations in the form of pleurisy,  interstitial fibrosis, nodular lung 
disease, bronchiolitis, pulmonary hypertension and small airways  disease.  
Cardiac  complications  include pericarditis,  myocarditis,  endocardial 
inflammation,  conduction defects, coronary  arteritis,  granulomatous 
arteritis  or valvular disease. 
 DIAGNOSIS                                   
1987 ACR Criteria for the Classification of Acute Arthritis of 
Rheumatoid Arthritis 25   
For classification purposes, a patient is said to have RA if he or she has 
satisfied at least 4 of the following 7 criteria. Criteria 1 through 4 must have 
been present for at least 6 weeks. Patients with 2 clinical diagnoses are not 
excluded. 
1. Morning stiffness: Morning stiffness in and around the joints, lasting at  
           least 1 hour before maximal improvement. 
2. Arthritis of 3 or more joint areas: At least 3 joint areas simultaneously           
have had soft tissue swelling or fluid (not bony overgrowth alone)           
observed by a physician; the 14 possible joint areas are right or left           
proximal interphalangeal (PIP)joints, metacarpophalangeal (MCP) 
 
 
joints, wrist, elbow, knee, ankle, and metatarsophalangeal (MPT) 
joints. 
3. Arthritis of hand joints: At least one area swollen (as defined above) in 
a  wrist,  MCP or PIP joint. 
4. Symmetric arthritis:  Simultaneous involvement of the same joint areas          
(see 2 above) on both sides of the body (bilateral involvement           
of PIPs, MCPs, or MTPs is acceptable without absolute symmetry). 
5. Rheumatoid nodules: Subcutaneous nodules, over bony prominences, 
or extensor surfaces, or in juxta-articular  regions, observed by a 
physician. 
6. Serum rheumatoid factor: Demonstration of abnormal amounts of 
serum rheumatoid factor by any method for which the result has been 
positive in  <5% of normal control subjects. 
7. Radiographic changes: Radiographic changes typical of RA 
on posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized to or most 
marked adjacent to the involved joints(osteoarthritis changes alone do 
not qualify) 
 
 
 
Various inflammatory disorders of remote organ systems may be present 
and may contribute to the presenting problem. Organ systems that may be  
affected include the following: 
• Cardiac - Carditis, pericarditis 
• Pulmonary - Pleuritis, intrapulmonary nodules, interstitial fibrosis 
• Hepatic – Hepatitis 
• Ocular -Scleritis, episcleritis, dryness of the eyes 
• Vascular – Vasculitis 
• Skin - Subcutaneous nodules, ulcers. 
LABORATORY STUDIES19 
 
• Complete blood count (CBC) indicates the presence of anemia in 
approximately 80% of patients with rheumatoid arthritis (RA). 
•  The anemia is normocytic and normochromic. 
• Thrombocytosis may be present. 
• Erythrocyte sedimentation rate (ESR) is elevated in approximately 
90% of patients with rheumatoid arthritis.  
• Serum RF result is positive in approximately 70% of patients with 
rheumatoid arthritis. Antinuclear antibodies (ANA) are present in 
approximately 30% of patients with rheumatoid arthritis.  
• Anti cyclic citrullinated antibody test is the latest addition to the list of  
 
 
 
laboratory investigations. It may be positive in 60% of seronegative 
RA if  second generation ELISA kit is used.  
TREATMENT(19,24,26,30) 
 
         
                       Treatment of rheumatoid arthritis comprises of non 
pharmacological and pharmacological therapies. It should have 
comprehensive regime directed towards treating the basic disease and the 
complications.  Non drug therapy includes  patient  education, counseling and 
rehabilitative measures that that focus on pain control, patient adherence, rest, 
joint protection principles and exercise therapy. 
                             Drug therapy includes analgesics, nonsteroidal anti-
inflammatory drugs, corticosteroids either intra articular or systemic.  
                                Current recommendations have become more aggressive 
in that, for all but minor disease, the use of DMARDs and/or biologic 
response modifiers or combination drug therapy earlier in the disease course 
is recommended in order to effectively slow or halt ongoing tissue damage. 
                              The American College of Rheumatology established 
recommendations for the use of nonbiologic and biologic DMARDS in 2008. 
These guidelines are broken down by disease severity and by duration of 
disease presence at less than 6 months, 6 months to 24 months, or greater 
 
 
than 24 months. The use of nonbiologic DMARDS is recommended early in 
the management (<6 months) of patients even with low disease activity and 
no features of poor prognosis. The use of combination DMARD therapy is 
phased in early and the further consideration of biologic DMARDS is 
recommended early if there are signs of high disease activity or features of 
poor prognosis. 
                                Nonbiologic  DMRDs  include  methotrexate , 
glucocorticoids, leflunomide ,  sulfasalazine,  cyclophosphamide,      hydroxy 
chloroquine,   gold injections,  d-penicillamine,   minocycline , azathioprine 
&cyclosporine. 
                                Biologic DMARDs include etanercept , adalimumab , 
abatacept, efalizumab, infliximab , rituximab , and certolizumab.    
                                Systemic steroids are usually used as low dose daily 
therapy or high dose short course therapy as for drug induced 
thrombocytopenia, mononeuritis multiplex and interstitial lung disease, 
coronary arteritis.  It can be used as a principal therapy during pregnancy 
when needed.  The drugs used in the combination triple drug therapy are 
methotrexate, hydroxychloroquine and sulphasalazine.  
                                  Other drugs like leflunomide, cyclosporine, 
azathioprine, D-penicillamine and gold salts are used either alone or in 
 
 
combination when the conventional DMARD combination therapy fails. The 
TNF α receptor antagonist  Etanercept  is a fusion protein of the soluble 
portion of the human TNF p75 chain of the receptor and the Fc portion of the 
human Ig G1 is used in patients who fail to respond to first line drugs and is 
shown to have higher improvement at ACR 20,50,70 responses. Infliximab, a 
chimeric monoclonal antibody has also been shown to reduce the clinical 
signs and symptoms along with slowing the radiological progression. 
Adalimumab is a fully humanized monoclonal antibody against TNF. 
Another drug is abatacept, a fusion protein of CTLA4 with  IgG.   Rituximab,  
an anti CD 20 B cell depleting agent have shown to have favorable results on 
the clinical as well as radiological progression of the disease.  Statins  were 
found to have beneficial effects in RA. Drugs which are under trial include 
p38 MAP kinase inhibitor, anit B cell stimulator (BLyS) and other anti 
cytokine therapies. 
COMPLICATIONS19 
 
• Felty syndrome  is a triad of RA, neutropenia, and splenomegaly. 
Patients with Felty syndrome are prone to serious bacterial infections 
that result in higher rates of morbidity and mortality than for other 
patients with RA. This requires prompt diagnosis and initiation of 
antibiotic therapy. 
 
 
 
• Ruptured Baker cysts  are often confused with deep vein thrombosis 
(DVT). Baker cysts often occur fairly early in the course of the disease, 
with pain, edema, and inflammation in the posterior knee and calf.  The 
diagnosis is best made with ultrasonography. Treatment includes rest, 
elevation, needle puncture of the calf, knee joint aspiration, and 
referral. 
• Carpal tunnel syndrome (median nerve compression neuropathy) is 
evidenced by pain and/or paresthesias in the median nerve distribution 
of the hand, a positive Phalen and/or positive Tinel test, or positive 
electromyography. Therapy includes rest, temporary immobilization, 
NSAIDs, and surgery. 
• Cervical spine instability may be observed in patients with 
established RA who have degeneration of the ligaments and bone in 
the C-spine area. Degeneration of the transverse ligament can lead to 
instability at the C1-C2 level. Minor trauma can lead to neurologic 
sequelae due to inherent instability.  
• Keratoconjunctivitis sicca  occurs in approximately 25% of patients 
with RA. Symptoms include ocular discharge, foreign body sensation, 
and dry eye. Episcleritis may progress to scleromalacia if untreated. 
Treatment includes referral to ophthalmology, artificial tears, systemic 
NSAIDs, topical NSAIDs, systemic steroids, and cyclophosphamide. 
 
 
 
• Patients with an established diagnosis of RA who are being treated 
with DMARDS, particularly those treated with combination therapy 
including the biologic response modifying agents such as anti-TNF 
antibody therapy, may present with serious infections and/or 
malignancies. 
• Additionally, adverse events from RA medications may include liver 
toxicity, renal toxicity, bone marrow depression, lung inflammation, 
and skin manifestations. 
• Cardiovascular morbidity and mortality are enhanced in rheumatoid 
arthritis, which might be due to an increased prevalence of 
cardiovascular risk factors such as dyslipidemia. 
DYSLIPIDEMIA44,45,46,47,48     
Dyslipidemia is a disorder of lipoprotein metabolism, including 
lipoprotein overproduction or deficiency. Dyslipidemias may be manifested 
by elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) 
cholesterol and the triglyceride concentrations, and a decrease in the "good" 
high-density lipoprotein (HDL) cholesterol concentration in the blood.  
Serum cholesterol is distributed mainly among three major lipoprotein 
classes:  
 
 
Very  low  density  lipoproteins   (VLDL) ,  Low  density      
lipoproteins (LDL),  &  High density lipoproteins (HDL), with small amounts 
in  intermediate density  lipoproteins (IDL) and lipoproteins (a) .   About 60–
70% of cholesterol is contained in LDL. 
                         Chylomicrons, the least dense type of cholesterol transport 
molecules, contain apolipoprotein B-48, apolipoprotein C, and apolipoprotein 
E in their shells. Chylomicrons are the transporters that carry fats from the 
intestine to muscle and other tissues that need fatty acids for energy or fat 
production. Cholesterol which is not used by muscles remains in more 
cholesterol-rich chylomicron remnants, which are taken up from the 
bloodstream by the liver.49,50 
                            VLDL molecules are produced by the liver and contain 
excess triacylglycerol and cholesterol that is not required by the liver for 
synthesis of bile acids. These molecules contain apolipoprotein B100 and 
apolipoprotein E in their shell. During transport in the bloodstream, the blood 
vessel cleave and absorb more triacylglycerol from IDL molecules, which 
contain an even higher percentage of cholesterol. The IDL molecules have 
two possible fates: Half are into metabolism by HTGL, taken up by the LDL 
receptor on the liver cell surfaces and the other half continue to lose 
 
 
triacylglycerols in the bloodstream until form LDL molecules, which have 
the highest percentage of cholesterol within them. 
                                 LDL molecules, therefore, are the major carriers of 
cholesterol in the blood, and each one contains approximately 1,500 
molecules of cholesterol ester. The shell of the LDL molecule contains just 
one molecule of apolipoprotein B100, which is recognized by the LDL 
receptor in peripheral tissues. Upon binding of apolipoprotein B100, many 
LDL receptors become localized in clathrin-coated pits. Both the LDL and its 
receptor are internalized by endocytosis to form a vesicle within the cell. The 
vesicle then fuses with a lysosome, which has an enzyme called lysosomal 
acid lipase that hydrolyzes the cholesterol esters. Now within the cell, the 
cholesterol can be used for membrane biosynthesis or esterified and stored 
within the cell, so as to not interfere with cell membranes.51,52, 
                                   HDL particles are thought to transport cholesterol back 
to the liver for excretion or to other tissues that use cholesterol to synthesize 
hormones in a process known as reverse cholesterol transport (RCT). Having 
large numbers of large HDL particles correlates with better health outcomes. 
In contrast, having small numbers of large HDL particles is independently 
associated with atheromatous disease progression within the arteries.53,54 
 
 
 
Purpose of  lipid tests 55,56,57,58 
                    The  purpose  of  blood  lipid  testing  is  to  determine whether 
abnormally high or low concentrations of a specific lipid are present. Low 
levels of cholesterol are associated with liver failure and inherited disorders 
of cholesterol production. Cholesterol is a primary component of the plaques 
that form in atherosclerosis and is therefore the major risk factor for the rapid 
progression of coronary artery disease (CAD). High blood cholesterol may be 
inherited or result from such other conditions as biliary obstruction, diabetes 
mellitus, hypothyroidism, and nephrotic syndrome. In addition, cholesterol 
levels may be increased in persons who eat foods that are rich in saturated 
fats and cholesterol, and who lead a sedentary lifestyle.  
                                To measure LDL-cholesterol directly, the LDL fraction 
in the serum has to be isolated by ultracentrifugation, followed by 
measurement of  the cholesterol content.  The process requires complicated 
technique and costly instrumentation.  In contrast, the Friedewald method 
doesnot require additional measurement other than total cholesterol, HDL-
cholesterol, and triacylglycerol.  Prolongation of fasting time beyond 12 h is 
not necessary for determination of blood lipid levels.59,60 
LDL cholesterol is estimated by use of the Friedewald formula: 
LDL-C    =   [  Total-C - HDL-C - (0.2 x TGL) ] 
 
 
                                 Low levels of triglyceride are seen in persons with 
malnutrition or malabsorption. Increased levels are associated with diabetes 
mellitus, hypothyroidism, pancreatitis, glycogen storage diseases, and 
estrogens. Diets rich in either carbohydrates or fats may cause elevated 
triglyceride levels in some persons. Although triglycerides are not a 
component of the plaque associated with atherosclerosis, they increase the 
viscosity (thickness) of the blood and promote obesity, which can contribute 
to coronary disease. The majority of cholesterol and triglyceride testing is 
performed to screen persons at increased risk of coronary artery disease.61,62  
Precautions before performing lipid tests63,64                                                                              
                                      Tests for triglycerides and LDL cholesterol must be 
performed following a 12-hour fast. Acute illness, high fever, starvation, or 
recent surgery lowers the blood cholesterol and triglyceride levels. If 
possible, patients should also stop taking any medications that may affect the 
accuracy of the test.  
                                       Patients who are scheduled for a lipid profile test 
should fast (except for water) for 12 to 14 hours before the blood sample is 
drawn. If the patient's LDL cholesterol is to be measured, he or she should 
also avoid alcohol for 24 hours before the test. When possible, patients 
should also stop taking any medications that may affect the accuracy of the 
 
 
test results. These drugs include  corticosteroids  ; estrogen or androgens; oral 
contraceptives; some diuretics ; antipsychotic medications, including 
haloperidol; some antibiotics ; and niacin. Antilipemics are drugs that lower 
the concentration of fatty substances in the blood. When these medications 
are taken by the patient, blood testing may be done frequently to evaluate 
liver function as well as lipid levels.  
ATP III Guidelines32 
                                 To  determine  lipoprotein  levels– obtain complete  
lipoprotein profile after 9- to 12-hour fast. 
ATP III Classification of LDL, Total, and HDL Cholesterol 
(mg/dL) 
Primary Target of Therapy32,33 
 
LDL Cholesterol  
  
<100       Optimal 
100-129  Near optimal/above optimal 
130-159  Borderline high 
160-189  High 
>190       Very high 
 
Total Cholesterol 
 
<200        Desirable 
200-239  Borderline high 
>240        High 
 
 
HDL Cholesterol 
 
<40         Low 
>60         High 
 
Serum Triglycerides (mg/dL) 
 
<150        Normal 
150-199   Borderline high 
200-499   High 
>500        Very high 
 
 
Comparison of LDL Cholesterol and Non-HDL Cholesterol 
Goals for Three Risk Categories 
 
 
 
Risk Category LDL Goal (mg/dL) Non-HDL Goal 
(mg/dL) 
CHD and CHD Risk   
Equivalent (10-year risk 
for CHD  >20%) 
 
<100 <130 
Multiple (2+) Risk 
Factors and 
10-year risk <20% 
 
<130 <160 
0-1 Risk Factor <160 <190 
 
(CHD risk equivalent) 
• Clinical CHD 
• Diabetes is regarded as a CHD risk equivalent. 
• Symptomatic carotid artery disease 
 
 
• Peripheral arterial disease 
• Abdominal aortic aneurysm 
Major Risk Factors (Exclusive of LDL Cholesterol) That 
Modify LDL Goals65,66 
 
• Cigarette smoking 
• Hypertension (BP >140/90 mmHg or on antihypertensive medication) 
• Low HDL cholesterol (<40 mg/dL)* 
• Family history of premature CHD (CHD in male first degree relative 
<55 years; CHD in female first degree relative <65 years) 
• Age (men >45 years; women >55 years) 
• HDL cholesterol >60 mg/dL counts as a “negative” risk factor; its 
presence removes one. 
Importantly, the reduction in HDL-C has as a consequence the increase 
in the TC/HDL-C ratio. This ratio represents an atherogenic index, which is 
an important prognostic marker for cardiovascular disease.[15] Indeed, the risk 
of myocardial infarction increases considerably when this ratio is higher than 
five, and it should ideally be four or less.[33] The serum TC and HDL-C levels 
in RA are inversely correlated with disease activity suggesting a potential 
role for inflammation in the atherogenic profile and the higher atherosclerotic 
risk observed in RA.33 
 
 
 
Total Cholesterol/HDl Cholesterol67,68 
                                   This ratio becomes high when the total cholesterol 
increases and HDL cholesterol decreases. Low ratio indicates lower risk of 
heart attack, while high ratio indicates higher risk. The total/HDL becomes 
low for low total cholesterol and high HDL cholesterol values. The safe 
total/HDL ratio is less than 4.  Total/HDL is more commonly obtained 
because the total cholesterol is easier and cheaper to obtain. A value more 
than 5 indicates high risk for coronary artery disease. 
LDL/HDL Ratio  
[LDL Cholesterol / HDL Cholesterol] 
                                    The LDL/HDL ratio is more important ratio than total 
cholesterol/HDL because LDL is a measure of bad cholesterol and HDL is a 
measure of good cholesterol. LDL/HDL is therefore an accurate measure of 
heart disease although it is costly to measure LDL cholesterol.   
 The risk levels of different values of LDL/HDL ratios are: 
Risk Level                      LDL/HDL Ratio 
Low risk                                3.3 - 4.4  
Average risk           4.4 - 7.1 
Moderate risk        7.1 - 11.0 
High risk          >11.0 
 
 
                                           The role of LDL-C in the pathogenesis of CHD 
has been established. Nevertheless, there are some patients with CHD with 
plasma LDL-C levels within the normal range. The variation in size, density, 
and composition of the LDL-C particle governs its properties. The use of 
gradient gel electrophoresis has demonstrated the existence of two distinct 
LDL-C phenotypes. The larger, less dense particles are known as pattern A 
and the smaller, denser particles are known as pattern B. These small, dense 
LDL-C particles are more prevalent in patients with the atherogenic 
metabolic syndrome (low HDL-C and high TG levels) and those with 
CHD.35,36,37,38 
                         Within the realms of the standard lipid profile, non-HDL appears 
to be the parameter correlating best with apo B. It therefore appears prudent 
to establish non-HDL-C as a target for modification of CVD death risk. 
                     In both males and females, non-HDL-C predicted CVD death 
better than LDL-C, with increasing levels of non-HDL-C corresponding to an 
increased risk of CVD mortality. In addition, for female patients, only HDL-
C and non-HDL-C significantly predicted CVD death, while the currently 
targeted lipoprotein, LDL-C, did not correlate with outcomes. In fact, LDL-C 
levels were the least reliable predictor of CVD deaths in women, when 
compared with non-HDL-C and HDL-C.38 
 
 
                                                         HDLs are particles with numerous atheroprotective 
functions, including facilitation of reverse cholesterol transport, improvement 
of  endothelial  function,  protection of  LDL from  oxidation , limitation  of  
hemostasis and retardation of inflammatory activity related to the vascular 
wall.                                    
                                 During the last decade interest has focused on 
apolipoprotein A-1 (apo A-1), apolipoprotein B (apo B) and lipoprotein(a) 
(Lp(a). Apo A-1 is the protein present on the HDL-C particles, whereas apo 
B is found on the LDL-C, very low density lipoprotein (VLDL) and 
chylomicrons particles. Hence, assessment of plasma apo A-1 and apo B 
allow an assessment of the total number of anti-atherogenic and atherogenic 
particles, respectively. Lp(a) is modified form of LDL in which apo A-1 is 
bound to apo B. 
                    There is some evidence that apo B might be a better 
predictor for cardiovascular events than LDL-C and that the apo B/apo A-1 
ratio is an accurate risk factor for cardiovascular disease (Rader et al 1994; 
Walldius and Jungner 2006)91. In other words: Apo A-1 might protect against 
cardiovascular disease whereas apo B might increase the cardiovascular risk. 
 
 
 
 
 
 
 
 ATHEROSCLEROSIS69,70,71 
                                  Atherosclerosis  is  a  multifactorial  and  dynamic 
process.  One of its feature is the presence of fatty streaks along the vessel 
wall leading to build-up of plaques on the wall of arteries, which leads to 
reduction in caliber of vessels. 22,23   Vasomotor function, the thrombogenicity 
of the blood vessel wall, the state of activation of the coagulation cascade, the 
fibrinolytic system, smooth muscle cell migration and proliferation, and 
cellular inflammation are complex and interrelated biological processes that 
contribute to atherogenesis and the clinical manifestations of 
atherosclerosis.22,23 
                                         The lesions of atherosclerosis do not occur in a 
random fashion. Hemodynamic factors interact with the activated vascular 
endothelium. Fluid shear stresses generated by blood flow influence the 
phenotype of the endothelial cells by modulation of gene expression and 
regulation of the activity of flow-sensitive proteins.  
                                    Atherosclerotic plaques characteristically occur in 
regions of branching and marked curvature at areas of geometric irregularity 
and where blood undergoes sudden changes in velocity and direction of flow. 
Decreased shear stress and turbulence may promote atherogenesis at these 
important sites within the coronary arteries, the major branches of the 
 
 
thoracic and abdominal aorta, and the large conduit vessels of the lower 
extremities. 
The physical signs of atherosclerosis provide objective evidence of 
extracellular lipid deposition, stenosis or dilatation of large muscular arteries, 
or target organ ischemia or infarction. 
Hyperlipidemia - Xanthelasma, tendon xanthomata 
Coronary artery disease - Fourth heart sound, tachycardia, hypotension, 
hypertension 
Cerebrovascular disease - Diminished carotid pulses, carotid artery 
bruits, focal neurological deficits 
Peripheral vascular disease - Decreased peripheral pulses, peripheral 
arterial bruits, pallor, peripheral cyanosis, gangrene, ulceration 
Abdominal aortic aneurysm - Pulsatile abdominal mass, peripheral 
embolism, circulatory collapse. 
Atheroembolism - Livedo reticularis, gangrene, cyanosis, ulceration (The 
presence of pedal pulses in the setting of peripheral ischemia suggests 
microvascular disease and includes cholesterol embolization.) 
Valvular heart disease (particularly calcific aortic stenosis, now 
recognized to be linked to atherosclerosis) – Cardiac murmur 
 
 
Dyslipidemia & accelerated atherosclerosis in rheumatoid 
arthritis 
Cardiovascular manifestations are frequent in rheumatoid arthritis 
(RA) and significantly contribute to morbidity and mortality in this disorder. 
Premature atherosclerosis is responsible for these complications, as supported 
by autopsy studies. Moreover, a high prevalence of sub-clinical 
atherosclerosis, as evaluated by imaging and instrumental parameters, has 
been reported. Traditional risk factors cannot completely account for 
accelerated atherosclerosis in RA.72,73,74 
Factors for CV events in RA  includes mainly  classical risk factors 
for CAD  as in general population, dyslipidemia , long term use of steroids , 
older age of diagnosis and long disease duration and persistent disease 
activity.17  
Immunological  and  metabolic  laboratory  markers,  anticyclic 
citrullinated  peptide (anti-CCP)  antibodies,  IgM rheumatoid factor,  
circulating immune  complexes,  pro-inflammatory  cytokines  including 
tumor  necrosis factor-α  (TNF-α)  and interleukin-6  (IL-6),  Th0/Th1 T  
cells,  high homocysteine,  dyslipidemia, decreased  folate and vitamin B12 
production, and impaired  paraoxonase  activity may all be involved  in  the  
development  of vascular disease in RA.  
 
 
 
 
 
                                                              In general, and with some variations between 
different studies, the lipid profile of patients with active or untreated RA is 
primarily characterized by a decrease in serum levels of HDL-C whereas 
contrasting results have been published on the serum levels of TC, TGL and 
LDL-C. Importantly, the reduction in HDL-C has as a consequence the 
increase in the TC/HDL-C ratio. This ratio represents an atherogenic index, 
which is an important prognostic marker for cardiovascular disease. Indeed, 
the risk of myocardial infarction increases considerably when this ratio is 
higher than five, and it should ideally be four or less. The serum TC and 
HDL-C levels in RA are inversely correlated with disease activity, suggesting 
 
 
a potential role for inflammation in the atherogenic profile and the higher 
atherosclerotic risk observed in RA.15 
                                    The cholesterol ester transfer protein (CETP) has a 
central role in HDL metabolism and in the regulation of HDL-C levels in 
serum. CETP exchanges cholesterol esters with triglycerides between HDL 
and apolipoprotein B-containing lipoproteins and thus significantly 
contributes to the reverse cholesterol transport pathway.  High levels of 
CETP activity lead to a reduction in HDL-C levels and an atherogenic 
lipoprotein profile.15   The role of this plasma protein in HDL metabolism is 
highlighted by the discovery that genetic CETP deficiency is the main cause 
of high HDL-c levels in Asian population.75  Torcetrapib, a CETP inhibitor,  
was a drug  being developed to treat hypercholesterolemia. Its development 
was halted in 2006 when phase III studies showed excessive all cause 
mortality in the treatment group receiving a combination of atorvastatin and 
the study drug.18 
                                                     Nevertheless, rheumatoid arthritis patients appear to 
have a high prevalence of abnormal blood lipid profiles—and given that so 
few of our patients were receiving lipid-lowering therapy, it is clear that we 
are not managing traditional risk factors for cardiovascular disease as part of 
our routine care.39                                
 
 
                                  Data from the trial of atorvastatin in rheumatoid arthritis 
demonstrated that patients who received atorvaststin 40 mg had improvement 
in disease severity scores, swollen joint counts, and inflammatory markers 
with no increase in adverse events compared to placebo.39  Whilst the routine 
use of statins as disease-modifying therapy for patients with rheumatoid 
arthritis is not yet routine,  practising their use in selected patients with 
abnormal lipid profiles could also benefit their arthritis.    
                     Patients with RA have a higher prevalence of the 
metabolic syndrome than control subjects. Inflammation-associated 
metabolic syndrome is a mechanism that may contribute to increased 
coronary-artery atherosclerosis in RA.   
             
                                  In many studies, early RA patients exhibited higher 
serum levels of (TC),  (LDL-C)  and TGL  compared to controls.  (HDL-C)  
levels were  significantly lower  compared to controls.15  Importantly, the 
serum HDL- C  and apoA-I levels were  significantly lower compared to 
controls.  As  a  consequence, the atherogenic ratio of TC/HDL-C as well as 
that of  LDL-C/ HDL-C was significantly higher in  ERA patients compared 
to controls.    
 
                                  Analysis of blood  samples from blood  donors who  
later  went on to develop rheumatoid arthritis (in a  recent  dutch  study )  
 
 
showed that,  their total cholesterol was higher,  HDL was lower and  TGL 
were  higher than levels of controls.11   As  inflammation  only marginally  
explains the  differences between  the two groups,  a modulating  effect of 
lipids on  inflammatory processes is hypothesised.  
                                  The dyslipidemia observed in RA appears to be 
dependent on disease activity, ie, a higher disease activity is associated with 
lower total cholesterol levels and even more depressed high density 
lipoprotein levels, leading to a higher (ie, unfavorable) atherogenic index. It 
appears that this dyslipidemia is already present long before the clinical onset 
of rheumatoid arthritis.9 
                       This  decrease  in  TC  and  LDL  levels  might  result  from their  
increased catabolism or  increased  retention ( ie,   subendothelial deposition )  
rather  than   decreased   lipid  production.   Subendothelial   lipid deposition  
might explain  the paradox of  lower cholesterol levels and increased CV risk 
in RA. Indeed,  low cholesterol concentrations have been previously 
associated with high  mortality risk  and a poor response to tissue stress.76,77  
Reduced levels of the lipid soluble antioxidant alpha-tocopherol (in RA 
patients) which terminates the process of lipid peroxidation, points to 
increased oxidative activity.  In RA patients, low levels of HDL-cholesterol 
have been found, which return to normal with treatment. However there are 
 
 
conflicting results for levels of other lipoprotein in RA, which may be 
explained by steroid treatment, renal disease and altered catabolic states.10  
                                Systemic inflammation may also play a role in the 
development of atherosclerosis . In fact, the increase of acute phase reactants 
in cardiovascular events has already been documented. It has even been 
suggested that RA and atherosclerosis may share a common predisposition 
factor ; CRP is the common denominator for both diseases . CRP, which 
increases in active disease, may contribute to atherosclerosis because it 
stimulates macrophages to produce tissue factor, a procoagulant that is found 
in atherosclerotic plaques. The presence of CRP in atheromatic lesions also 
suggests a 'cause and effect' relationship between this acute phase reactant 
and coronary events.15 
                              Corticosteroids, on  the  other  hand,  have  a  potentially   
atherogenic effect, given that they cause dyslipidemia and hypertension . In  
spite of this, the effect of  their  long-term  administration  in  RA is not  yet  
completely  understood. 
                               Several  studies  have  been unable  to demonstrate any 
association between cardiovascular mortality  and the use of corticosteroids . 
A  recent study reported a  small  or  no  increase  in  TC  levels  during  
long-term administration  of corticosteroids 16.    Corticosteroids can contribute 
 
 
to a type 2b hyperlipidaemia. The   triglyceride   level ,   LDL  and  HDL  
values  may  often  rises  with  prednisolone  treatment.10 
                                  ERA patients are characterized by an atherogenic lipid 
profile, which improves after therapy. Thus, early  immuno-intervention to  
control disease  activity  may  reduce  the  risk  of  the  atherosclerotic  
process and cardiovascular events in ERA patients.15   
Carotid artery intima media thickness ( CIMT ) 
                                Carotid intima-media thickness (cIMT) reflects early 
atherosclerosis and predicts cardiovascular events in the general population. 
An increased cIMT is present in patients with rheumatoid arthritis, compared 
with control individuals, from the early stages of the disease and is thought to 
indicate accelerated atherosclerosis, but direct evidence is not available. 
Whether cIMT is susceptible to rapid and potentially reversible change 
depending on the intensity of inflammation in states of high-grade systemic 
inflammation, such as rheumatoid arthritis, remains unknown.8 
                                  Ultrasonographic evaluation of carotid artery intima 
media thickness (CIMT) allows the non-invasive and early detection of 
atherosclerotic changes and is used as a non-invasive end point for assessing 
the progression and regression of atherosclerosis in clinical  trials.  Because 
atherosclerosis is a systemic disease, assessment of carotid plaque by 
 
 
ultrasonography provides a robust, direct measure of systemic 
atherosclerosis.78 
                                                      Carotid IMT is related to coronary risk factors such as 
age, smoking, hypertension and LDL-Cholesterol. Several studies suggest 
that CIMT is of high value as a surrogate marker for generalized 
atherosclerosis and atherosclerosis of coronary arteries. Hence non-invasive 
ultrasonographic measurement of IMT can be of great value in screening for 
such asymptomatic patients suffering from RA.12                 
                               The CIMT has been shown in numerous studies to be a 
non-invasive, economical, reliable and sensitive marker for atherosclerosis. 
To measure the CIMT, duplex scanning of the carotid arteries is performed. 
This refers  to  the  use  of  Doppler  (to  estimate  blood  flow  
characteristics)  in conjunction with conventional 2-dimensional (B-mode) 
ultrasound. Depending on the scanning protocol used, specific pre-
determined bilateral sites in the vicinity of the carotid bifurcation are selected 
for measurement of parameters. The images obtained using the B-mode scan 
are then measured for the intima-media thickness, while the Doppler 
assessment is used to gauge the impedence to blood flow caused by the 
narrowing induced by the plaque. Use of computer software can provide a 
more accurate reading, a reduction in analysis time and elimination of inter-
observer bias.41,42 
 
 
                                                         Since arterial wall area incorporates both diameter and 
wall thickness, area estimation may provide some advantages to IMT alone . 
The relationship of plaques, IMT, and artery diameter is complex and a 
number of arterial phenotype classifications have been proposed. Risk factors 
are associated with arterial wall thickness, IMT progression, artery diameter , 
and calcified carotid plaques.                                      
                                      Correlations between carotid IMT and diameter (0.31 
to 0.62)  vary across populations and may depend upon whether the internal 
or external diameter 31 is evaluated. Part of the correlation may reflect an 
adaptive process used to maintain arterial wall stress, but in the presence of 
vulnerable atherosclerotic plaques, arterial diameter may reflect direct 
damage of the internal elastic lamina and arterial media 36,37.  So, risk factors 
may contribute to IMT and diameter directly and indirectly. 
                                       Given the strong body of evidence for its use, carotid 
doppler and CIMT should become routine screening tools for atherosclerosis 
in India. We have a population with a high incidence of diabetes, a high 
prevalence of dyslipidemia and, with increasing urbanization, an 
everincreasing population with detrimental lifestyle changes.   
                                              It provides a noninvasive, readily available 
method to image the major arteries of the neck. Its validity as a measure of 
atherosclerosis is supported by 3 lines of evidence: 
 
 
          (1) the correlation between ultrasound and histological measurements of 
arterial intima-media thickness (IMT);(2) the correlation between histological  
 measurements of carotid and coronary wall IMT; and (3) the association 
between CV risk factors and ultrasound measurements of carotid IMT, and 
the ability of the latter to predict CV events in the general population.84,85                            
                                       A relatively new measure, the coronary artery inter-
adventitial distance, is also being evaluated and has been found to be a good 
predictor of cardiovascular risk. Recently, the ankle-brachial index has also 
been studied as a clinical aid to estimate subclinical atherosclerosis and its 
use has been suggested as a precursor to CIMT measurement.43   
 
DYSLIPIDEMIA & ATHEROSCLEROSIS – MEDICATION25 
           The most common type of medicine to treat 
hypercholesterolemia are 'statin' drugs. They work by inhibiting the 
enzyme HMG-CoA  Reductase. Statin drugs lower the amount of LDL  
cholesterol in the blood which stops atherosclerosis from getting worse. 
Statin drugs can even help make atherosclerosis better. However, statins are 
not as good at increasing the HDL cholesterol. Low HDL is hard to treat with 
medicines, but goes up with more exercise!  Statins can cause liver problems 
and damage to muscle cells. 
 
 
          Fibrates are used in (STATIN+) combination therapy & also 
as monotherapy agents.  Fibrates reduce the number of non-fatal heart 
attacks, but do not improve all-cause mortality and are therefore only 
indicated in those not tolerant to statins.  Although less effective in lowering 
LDL, fibrates improve HDL and triglyceride level and seem to improve 
insulin resistance when the dyslipidemia is associated with other features of 
the metabolic syndrome. Fibrates are agonists of the PPAR-α receptor in 
muscle, liver, and other tissues. Most fibrates can cause mild stomach upset 
and myopathy. Since fibrates increase the cholesterol content of bile, they 
increase the risk for gallstones. 
           Bile Acid Resins (cholestyramine) are medicines that make 
people not absorb as much bile when they digest food. This causes them to 
take up less cholesterol also, which lowers blood levels of cholesterol.  
Niacin  is used to treat hypercholesterolemia.  Niacin is one of the 
medicines that may make HDL (good) cholesterol go up. The biggest 
problem with taking enough Niacin to help cholesterol is that it causes severe 
flushing (hot, red, sometimes itchy skin). Ezetimibe is a drug that acts by 
decreasing cholesterol absorption in the intestine. It may be used alone when 
other cholesterol-lowering medications are not tolerated, or together with 
statins when statins alone do not control cholesterol. 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
1)  To study the Serum Fasting Lipid Profile Pattern in Rheumatoid 
arthritis. 
2)  To estimate subclinical atherosclerosis in patients suffering from 
rheumatoid arthritis by measuring the carotid intima media thickness. 
3)  To study the association of age, duration of illness, CRP, disease 
activity& RA factor with dyslipidemia & carotid intima media 
thickness in these patients.  
4)  To analyse  lipid parameters and  CIMT and its correlation with DAS 
28 score. (Disease activity score)  
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
Setting                      :  Department of Medicine. Govt. Rajaji Hospital 
Design                      :  Cross–sectional case control study. 
Period of study         :  Six months (July 2010 to December 2010) 
Ethical approval       : Obtained from ethical committee   
                                     headed by Dean, Govt. Rajaji Hospital. 
Consent                    : Obtained from all patients. 
Statistical software   : EPI Info 2008. 
Study population      : Patients attending Rheumatology OP with  
    Rheumatoid  Arthritis- randomly selected. 
Inclusion criteria: 
1)  Patients who satisfied Revised American Rheumatologic Association  
criteria 1987, irrespective of  sex and duration of disease and with  age 
more than 18 years. 
2)  Forty healthy control subjects who were willing to participate after 
informed consent. 
Exclusion criteria: 
1) Patients already on lipid lowering medications. 
2) Previous history of coronary artery disease or cerebrovascular disease. 
 
 
3)  Those who had deranged liver function tests and those who are 
suffering from inherited disorders of lipid and lipoprotein metabolism 
and/or family history of such disorders. 
4) Serum creatinine level of 1.6 mg/dl or greater. 
5) Current or recent (within the past 3 months) pregnancy or use of OCPs. 
6) Patients who were smokers and/or alcoholics or with features of 
peripheral occlusive vascular disease who already took treatment. 
7) Patients who are known diabetics and/or hypertensives or detected now 
at the time of study. 
8) Patients on eltroxin or with clinical evidence of hypothyroidism. 
9) Those who have mixed disorder like SLE and RA; SS and RA; and 
MCTD and overlap syndrome. 
10) Obesity  ( body mass index >30 ). 
                           Forty two patients attending Rheumatology clinic, Govt. 
Rajaji Hospital, Madurai, who were diagnosed to have Rheumatoid Arthritis, 
and who satisfied the inclusion and exclusion criteria were selected for the 
study. 
                           Forty controls attending general medical op for minor 
ailments and who were otherwise healthy were also included. 
 
 
                                The selected patients were evaluated with history 
regarding the duration of disease, nature of symptoms, history of drug intake, 
and the type of onset of symptoms 
                                 Presence of joint swelling, tenderness, and deformities 
and number of tender joints, number of swollen joints were noted. Detailed 
clinical examination including pallor and rheumatoid nodules were done. All 
systems were examined carefully. Visual analogue pain score was carefully 
assessed. A detailed cardiovascular examination was done with special 
attention to blood pressure recording, carotid bruit and checking peripheral 
pulses and other markers of atherosclerosis. 
                            Serum Fasting Lipid Profile, Hemoglobin, White blood cell 
count, Differential count, Blood Urea,  Serum Creatinine,  Blood sugar,  
ESR,  LFT,  Rheumatoid Factor and C Reactive Protein by latex 
agglutination test , ECG , TSH, Chest X ray and Carotid  Doppler study of  
CCA & ICA to detect the mean CIMT were done for all patients.                              
                            Disease Activity Score, BMI,  Total Cholesterol / HDL & 
LDL / HDL  ratios were  calculated for every patients.  Carotid  Doppler 
study, Total Cholesterol / HDL & LDL / HDL  ratios were  calculated for all 
control subjects also. 
 
 
 
 
DAS 28 score  
                                 Disease activity score is a composite score using tender 
and swollen joint count, ESR and patient’s global assessment activity using a 
10 mm visual analogue scale.  
         DAS28= 0.56 √(tender joints) + 0.28√(swollen joints) 
                         + 0.70 Log (ESR) + 0.014(VAS in mm) 
Classification  
 
          Less Active   ≤ 3.1 
Moderate   3.2- 5.1 
Highly active  > 5.1     
(Minimum score= 0; Maximum score= 9) 
ASSESSMENT OF CAROTID INTIMA MEDIA THICKNESS(46)                                              
                                                Ultrasonographic scanning of the carotid arteries was 
performed using WIPRO – Ge logic 400 MD scanner with a linear transducer 
(midfrequency range 7.5 – 10 MHz). The patient being in supine position and 
the chest being elevated with a pillow and the head being turned to the 
opposite side of the carotids examined, the probe was placed on the medial 
side of the sternocleidomastoid muscle to identify the carotid vessel and the 
carotid bulb was traced. Intima media thickness was assessed at the site of 
maximum thickness in the CCA / Bulb / ICA.  
                              The carotid wall shows parallel echogenic lines separated 
by a hypoechoic region (media). The inner line is the lumen intima interface 
 
 
and the outer is the media adventitia interface. Carotid IMT was defined as 
the distance from the leading edge of the first echogenic line to the leading 
edge of the second echogenic line on the scans. Carotid IMT was measured 
on both sides and the average value was taken as the mean CIMT. IMT value 
of more than 0.7-0.8mm is suggestive of significant atherosclerosis.45 
Confict of interest  :  There  was no conflict of interest. 
Financial support   :   Nil 
Statistical analysis  :    
                             The information collected regarding all the selected cases 
were recorded in a Master chart in Microsoft Excel spread sheet. Data 
analysis was done with the help of computer using Epidemiological 
Information Package (EPI 2008). Using this software, range, frequencies, 
percentage, mean, standard deviation and p value were calculated. Kruskul 
Wallis chi-square test was used to test the significance of difference between 
quantitative variables and Yate’s test for qualitative variables.  A ‘p’ value 
less than  0.05 was taken as significant. 
 
 
 
 
 
 
 
RESULTS AND ANALYSIS 
 
Profile of total cases studied: 
• Majority of patients were from in and around Madurai city.  
• The  total number of patients included in the study was 42. 
          [ FEMALE (F)-33 ;  MALE (M)-9 ].   
• Fourty age and sex [F-30/M-10] matched controls from in and around 
Madurai were also included in the study for comparative analysis. 
• Mean age of study group was 40.2 years and that of control group was 
41.7 years.   
• Only  3  patients  had  no  previous  history  of  any  treatment. 
• Lipid profiles and CIMT of all patients were compared with the control 
group matched for sex, age, and body mass index. 
     
 
 
                  
 
 
 
TABLE – 1A 
     AGE GROUP DISTRIBUTION IN STUDY AND CONTROL 
GROUP 
 
     STUDY GROUP CONTROL 
GROUP 
TOTAL NO OF 
CASES 
42 40 
 Age group   
UP TO 20 YEARS 1 0 
21- 30 YEARS 4 5 
31-40 YEARS 17 12 
41-50 YEARS 12 14 
ABOVE 50 YEARS 8 9 
MEAN AGE 40.2 41.7 
P VALUE   -   0.654 (NOT SIGNIFICANT) 
 
Mean age of study group was 40.2 years and that of control group was 41.7 
years.     
There was no significant difference in age between study and control group 
 
 
TABLE 1B       SEX DISTRIBUTION IN BOTH GROUPS 
 
SEX 
 
              STUDY CASES            CONTROL CASES 
 NUMBER PERCENTAGE NUMBER PERCENTAGE
MALE 
 
9 21.4% 10 25% 
FEMALE 
 
33 78.6% 30 75% 
   
P VALUE -  0.677 ( NOT SIGNIFICANT ). There was no significant 
difference. 
 
 
 
 
 
 
TABLE  1C   -    
               DURATION OF ILLNESS IN STUDY GROUP 
 
  
DURATION (in 
years) 
NUMBER OF 
CASES 
 
PERCENTAGE 
0-5 23 54.8 % 
6-10 16 38.1 % 
>10 3 7.1   % 
TOTAL                  42 
MEAN DURATION 5.1 YEARS 
 
The mean duration of illness in the study was  5.1 years. 
 
 
TABLE 1D     HISTORY OF PREVIOUS TREATMENT      
 
 
HISTORY OF 
TREATMENT 
 
STUDY CASES 
NO. 
 
PERCENTAGE 
YES 39 92.9 % 
NO 3 7.1 % 
TOTAL                     42 
    
 Only 3 patients had no previous history of any treatment. 
 
TABLE 1E    CRP IN STUDY GROUP AND CONTROL GROUP 
 
CRP 
 
STUDY GROUP CONTROL 
GROUP 
POSITIVE 
 
37 8 
NEGATIVE 
 
5 32 
P VALUE 
 
0.0001(SIGNIFICANT) 
CRP significantly high in study group. 
 
 
 
 
 
 
TABLE 1F        
                      ESR IN STUDY GROUP AND CONTROL GROUP 
 
ESR 
 
Study group Control group 
Range 29-109 4-46 
Mean 60 16 
SD 18 10 
P VALUE  -   0.0001 ( SIGNIFICANT ) 
 
 The mean ESR value in RA patients was about 4 times higher when 
compared  to the control  population. 
 
 
TABLE  1G 
                    DAS SCORE AMONG STUDY GROUP 
 
 
DAS SCORE 
 
NUMBER 
[PERCENTAGE] 
<3.1 LESS 
ACTIVE 
6 14.3% 
3.2 – 5.1 
 
ACTIVE 20 47.6% 
>5.1 HIGHLY 
ACTIVE 
16 38.1% 
 
The mean DAS SCORE was 4.68.  
 
Sixteen patients had a highly active disease. 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE NO 2A 
 Table for biochemical and lipid profile in study and control subjects 
 
PARAMETER 
 
STUDY     
GROUP 
CONTROL 
GROUP 
P 
VALUE 
 
SIGNIFICANCE 
MEAN SD MEAN SD 
TOTAL 
CHOLESTEROL 
177.9 27.2 170.2 22.3 0.284 NOT 
SIGNIFICANT 
 
TRIGLYCERIDE 
151.1 33.4 117.4 22.6 0.0001 SIGNIFICANT 
 
VLDL 
30.9 7.4 23.5 4.5 0.0007 SIGNIFICANT 
 
HDL 
37.6 7.4 46.4 7.3 0.0001 SIGNIFICANT 
 
LDL 
108.9 25.4 100.4 18.9 0.105 NOT 
SIGNIFICANT 
NON-HDL CHO 
 
141.2 28.2 123.8 20.6 0.019 SIGNIFICANT 
BMI 21.1 2.2 22.9 2.0 0.641 NOT 
SIGNIFICANT
SYS.BP/DI BP 115/74 12/4 114/72 11/5 SBP 0.81 
DBP0.70 
NOT 
SIGNIFICANT 
Hemoglobin 11.0 1.4 11.6 1.5 0.069 NOT 
SIGNIFICANT 
Urea 30.1 6.1 29.5 6.7 0.673 NOT 
SIGNIFICANT
Creatinine 0.75 0.13 0.73 0.16 0.608 NOT 
SIGNIFICANT 
 
 
The Triglyceride level , VLDL level &  non – HDL cholesterol values were 
significantly higher in RA patients. 
 
HDL cholesterol values were significantly lower in RA patients. 
 
There was no significant difference in Total Cholesterol and LDL values 
between RA patients and the control population. 
 
 
 
 
 
 
 
TABLE 2 B  - CAROTID INTIMA MEDIA THICKNESS  AND  
       ATHEROGENIC   INDEX  IN STUDY & CONTROL GROUP 
 
 
GROUP 
CIMT (MM) LDL/HDL TOTAL 
CHOL/HDL 
(MEAN±SD ) (MEAN±SD ) (MEAN±SD ) 
RA 
PATIENTS 
0.68 ± 0.08 
 
3.24 ±0.95 5.44 ± 1.15 
CONTROL 
GROUP 
0.58 ± 0.07 2.08± 0.67 3.59 ± 0.78 
P VALUE 
 
0.032 
SIGNIFICANT
0.0001 
SIGNIFICANT
0.0001 
SIGNIFICANT
 
The CIMT was significantly higher in RA patients. 
 
The  LDL / HDL ratio was significantly higher in RA patients. 
 
The  Total Cholesterol / HDL ratio was also significantly higher in RA 
patients. 
 
 
 
TABLE 3A-    AGE & CAROTID INTIMA MEDIA THICKNESS IN  
                                          STUDY  & CONTROLS 
 
 
 
AGE GROUP 
 
 
CAROTID INTIMA MEDIA THICKNESS  (cm) 
STUDY GROUP 
 
CONTROL GROUP 
MEAN SD MEAN SD 
LESS THAN 20 YRS 0.6 0 --- --- 
21 – 30 YRS 0.6 0.07 0.56 0.06 
31 -  40 YRS 0.63 0.05 0.57 0.05 
41 -  50 YRS 0.67 0.05 0.58 0.04 
MORE THAN 50 YRS 0.71 0.07 0.62 0.06 
 
CIMT was higher in all age groups in RA patients when compared to control 
population 
 
 
 
TABLE 3B -  LIPID PROFILE & CIMT IN RA patients  & CONTROLS 
 
PARAMETER RA PATIENTS CONTROL  
GROUP 
NUMBER(42) PERCENT NUMBER(40) PERCENT 
TGL> 150 19 45.2% 05 12.5% 
LDL > 100 22 52.3% 19 47.5% 
HDL<40 26 61.9% 09 22.5% 
NON – HDL >160 06 14.3% 01 02.5% 
LDL/HDL>3 24 57.1% 02 05.0% 
TOT. CHO/HDL>4 32 76.2% 07 17.5% 
TOT. CHO/HDL>5 21 50.0% 02 05.0% 
CIMT>7.2 mm 13 30.9% 04 10.0% 
 
LDL, HDL, TRIGLYCERIDE LEVELS  cut off  limits taken according to 
NCEP–III   guidelines previously mentioned. 
 
Values of mean CCA IMT above mean + 2 SD of the control group were defined as 
abnormal IMT. This  Criteria is taken as in the study  mentioned from (J Rheumatol 
2006;33:244-7). August 28, 2005.  Sundeep grover etal  - A study on Subclinical 
Atherosclerosis in Rheumatoid Arthritis in India  , August 28, 2005. Prof. R. Misra, 
Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, 
Lucknow. 
 
¾ The CIMT more than upper limit was seen in 13 RA patients(30.9%) . 
            Among the RA group, 24 patients (57% ) had LDL / HDL ratio >3   
            Ten RA patients had LDL/HDL ratio > 4. 
¾ Interestingly, 21 RA patients (50% ) had Total Chol/ HDL ratio> 5 
while only 5% of control population had such an atherogenic profile. 
¾ HDL cholesterol values were lower(<40) in  26 (62%) of  RA patients 
as compared to only 22% of controls. 
¾ The triglyceride values were higher (45.2%) in RA group .There was 
no significant difference in LDL values. 
¾ Of  the 13 RA patients with CIMT > 7.2mm ,  SIX patients had 
LDL/HDL > 4 and SEVEN patients had TOTAL CHO/HDL > 5, and 
ELEVEN ( 85% ) patients had HDL level <40 mg/dl. 
 
 
 
 
 
Table  3C-  
  ATHEROGENIC INDEX &  CIMT  IN RELATION TO DAS SCORE 
     
There was no relation between DAS score and atherogenic index or CIMT 
values. 
 
 
TABLE 3D  -    DISEASE DURATION AND DYSLIPIDAEMIA AND 
CIMT 
 
DISEASE 
DURATION 
LDL/HDL 
( MEAN) 
TOTAL 
CHOLESTEROL/HDL 
( MEAN) 
CIMT ( mm ) 
( MEAN) 
FIVE OR LESS 
YEARS 
3.06 5.05 6.6 
MORE THAN 
FIVE YEARS 
3.48 5.68 7.4 
P VALUE 0.036 
(SIGNIFICANT ) 
0.015 
( SIGNIFICANT)
0.027 
(SIGNIFICANT )
 
RA patients with more than 5 years disease duration had a higher atherogenic 
index and higher CIMT than those with less than 5 years of illness. 
 
 
 
DAS 
SCORE 
 LDL/HDL TOTAL 
CHOL/HDL 
CIMT(mm) 
< 3.2 MEAN 3.45 5.54 6.9 
SD 0.35 0.73 0.7 
3.2 – 5.1 MEAN 2.60 4.8 6.6 
SD 0.42 0.6 0.8 
>5.1 MEAN 3.53 4.9 7.1 
SD 0.49 0.56 0.7 
P 
VALUE 
 0.3939 (NOT 
SIGNIFICANT) 
0.463 (NOT 
SIGNIFICANT) 
0.185 (NOT 
SIGNIFICANT) 
 
 
   
TABLE 4  
 
    COMPARISON  BETWEEN  CRP POSITIVE &  NEGATIVE 
CASES  
 
 
     PARAMETER 
CRP 
POSITIVE 
CRP 
NEGATIVE 
 
P VALUE 
MEAN SD MEAN SD 
TRIGLYCERIDE 156.5 38.9 147.1 30.8 0.261 (NOT 
SIGNIFICANT) 
LDL 112.3 26.6 105.8 21.2 0.171 (NOT 
SIGNIFICANT)
HDL 36.2 6.3 45.4 8.8 0.001 (SIGNIFICANT) 
NON HDL 149.2 31.5 138.9 24.4 0.193(NOT 
SIGNIFICANT) 
Total Cholesterol 184.3 27.3 171.9 23.1 0.078 (NOT 
SIGNIFICANT) 
LDL/HDL 3.33 1.0 2.31 0.8 0.0001(SIGNIFICANT)
TOTAL 
CHOL/HDL 
5.5 1.2 4.3 1.1 0.0003(SIGNIFICANT)
CIMT ( mm ) 7.1 0.56 6.8 0.46 0.195( NOT 
SIGNIFICANT) 
DAS SCORE 4.38 0.45 4.24 0.58 0.30(NOT 
SIGNIFICANT) 
 
Out of the total 42 study patients, 37 (88.1%)  were  CRP positive. 
 
The LDL / HDL ratio was significantly higher in CRP  POSITIVE  
patients. 
 
The Total Cholesterol / HDL ratio was significantly higher in CRP 
POSITIVE patients. 
 
HDL cholesterol values were significantly lower in CRP positive patients. 
  
There was no significant difference in Total Cholesterol, Triglyceride, Non-
HDL ,  LDL Cholesterol & CIMT values between CRP positive and negative 
patients. 
 
 
 
          
 
TABLE 5A 
 
              Rheumatoid factor positivity in study subjects 
 
RHEUMATOID 
FACTOR 
 
CASES  NUMBER PERCENTAGE 
POSITIVE 
 
33 79.5% 
NEGATIVE 
 
9 20.5% 
TOTAL 
 
42  
 
 Out of the 42 study patients  33 were RA FACTOR positive. 
 
 
TABLE 5B  
      
COMPARISON  OF  RA  FACTOR  POSITIVE & NEGATIVE CASES 
 
GROUP Total 
No  of 
subjects 
LDL / 
HDL 
 
MEAN 
Total Chol 
/ HDL 
MEAN 
C I M T 
(mm ) 
MEAN 
Mean 
Duration of 
illness 
(yrs) 
DAS 
SCORE 
MEAN 
RA  factor 
+ve 
33 3.29 5.52 7.0 5.15 4.32 
RA  factor 
-ve 
9 3.19 5.32 6.7 3.95 3.98 
P VALUE ----- 0.34 
(NOT 
SIGNIFICA
NT) 
O.29 ( NOT 
SIGNIFICANT) 
0.083 
(NOT 
SIGNIFICANT) 
0.22  (NOT 
SIGNIFICANT) 
0.067 
(NOT 
SIGNIFICANT) 
  
 
There was no significant difference in LDL/HDL RATIO, Total 
Cholesterol /  HDL ratio, DAS SCORE & CIMT values between rheumatoid 
factor positive and rheumatoid factor negative patients. 
 
 
 
 
DISCUSSION 
                                           Studies of myocardial infarction and other CV 
events in patients with rheumatoid arthritis (RA) have consistently found that 
their incidence is at least twice as high as in controls without RA.82,83  
                                                                    The first reports of ischemic heart disease 
morbidity in comparison with the general population were presented in 2001, 
when Del Rincón107 et al. showed that patients with  rheumatoid  arthritis  
suffered  an  almost  four-fold increased  risk  of cardiovascular events, 
incidence rate ratio 3.96 (95% confidence interval 1.86, 8.43) . They used an 
outcome definition including cerebrovascular disease, as well as ischemic 
heart disease, but in 2003 Solomon108 et al. presented data from the Nurses  
Health Study, suggesting that there indeed was an increased risk of ischemic 
heart disease (in this case, myocardial infarction) in the rheumatoid arthritis 
population.   
                                                                    An important metabolic feature of RA is the 
catabolic state leading to loss of body cell mass due to a accelerated loss of 
skeletal muscle (Walsmith109 et al 2004). This is known as rheumatoid 
cachexia and important mediators are TNFα and other proinflammatory 
enzymes. These mediators are also associated with  low TC and HDL-C 
levels (Kotler110 2000), and as a higher disease activity in RA is accompanied 
 
 
with a higher TNF level this might explain the relationship between disease 
activity and lipid levels. 
                                                              Our cross-sectional study was conducted in 42 
patients with RA in Govt. Rajaji Hospital, Madurai.  Lipid profiles and CIMT 
of all patients were compared with a control group matched for sex, age, and 
body mass index. Each patient was assessed through a self-reported 
questionnaire, structured interview and physical examination. Blood samples 
were obtained for routine biochemistry, lipid profile and haematological tests. 
                                       The sex distribution in this study, predominantly 
affects females in the ratio of 3.5:1. According to Harrison 17th edition, API 
text book of medicine, the females are affected 3 times more than males. In 
this study males are 22% and females are 78%. In Doran MF &Ponal et al 
study, males are 26.9% and females are 73.1%86. 
                                      The mean age in our study is 40.2years. Most  
number of cases is in between 31- 50years (69%). In a study conducted by 
Mary.J.Roman et al, average age of  patients was 35 years. The average age 
of patients in our study was comparable to that of other studies.87 
                                                           In this study, average duration of rheumatoid arthritis 
is 5.2 ± 3.5 years. Most number of patients had a duration between between 3 
-7 years of age (57%).  In a study by Anna Sodergren et al88, the mean age of 
 
 
study group were 37.6 years (Range 18-66) and the mean duration of 
rheumatoid arthritis was 3.6 years at the time of conducting CIMT testing. 
                                        In our study RF is positive in 80% of cases. There is  
no significant difference in LDL/HDL RATIO, Total Cholesterol / HDL 
ratio, Das Score & CIMT values between rheumatoid factor positive and 
rheumatoid factor negative patients. The reference analysis as suggested by 
Jane E. Salmon &  Dr. Targher90 et al also showed no association between 
autoantibodies (rheumatoid factor or anti-CCP antibodies) and the presence 
of carotid atherosclerosis in their patients. Carotid plaque was detected in 
49% of patients with positive results for rheumatoid factor and in 46% of 
patients with negative results for rheumatoid factor (P = 0.78), as well as in 
42% of patients with anti-CCP antibodies and 44% of those without anti-CCP 
antibodies (P = 0.84). Furthermore, although titers of anti-CCP antibodies 
may predict radiographic outcome and disease severity in rheumatoid 
arthritis, they did not predict carotid atherosclerosis. 
                                         In our study average DAS 28 score is 
4.68±0.74;most of the patients were having moderate severity (score between 
3.2- 5.1).  21 out of 45 patients (48%) were having moderate disease activity.  
38% of patients had severe disease activity according to DAS 28.  Carotti et 
al89  in their study reported 14.6% patients had mild disease, 48.4% had 
moderate DAS score and 45.5 % of patients had severe disease activity.  In 
 
 
our study there is no relation between DAS score and atherogenic index or 
CIMT values. In a study by Anna Sodergren et al88, there was no relation 
between the disease activity measurements, that is, DAS28 & HAQ and the 
ultrasound measurements in the RA patients at the time of the baseline 
investigation. In a study by Carotti et al89 no significant correlation was found 
for CIMT with clinical and laboratory parameters reflecting disease activity.        
                                       Out of the total 42 study patients, 37 (88.1%) 
are CRP positive. The LDL / HDL ratio is significantly higher in CRP 
positive  patients. The Total Cholesterol / HDL ratio is significantly higher in 
CRP positive patients.HDL cholesterol values are significantly lower in CRP 
positive patients. There was no significant difference in Total Cholesterol, 
Triglyceride, Non-HDL ,  LDL Cholesterol & CIMT values between CRP 
positive and negative patients.  In another study,  Dessein P.H92 et al showed 
that high C-reactive protein (CRP) concentrations were associated with 
insulin resistance and hypertension, while insulin resistance was a statistical 
predictor of low HDL cholesterol and high triglycerides.                                            
                                               One of the first controlled studies reporting on 
apolipoprotein levels in RA was performed in 42 untreated patients (mean 
disease duration 27 months) and 42 age- and sex-matched controls (Park et al 
1999)93. The investigators found significantly lower levels of apolipoprotein 
A1 and HDL-C in patients than in controls  and significantly higher levels 
 
 
Lp(a) (27.1 vs 18.0 mg/dL, respectively). The ratios of apo B/apo A1, total 
cholesterol/HDL-cholesterol were significantly higher in patients than in 
controls (0.82 vs 0.67, 4.4 vs 3.4, respectively). CRP levels had an inverse 
correlation with apolipoprotein A1 and HDL-C indicating an adverse effect 
of disease activity on lipid profile. Douglas White92  et al showed in their 
study that elevated ESR is associated with statistically significant alterations 
in HDL and LDL cholesterol levels, but this is not the case for elevated CRP 
where a relationship was only seen with reduced HDL levels.                                  
                                  In our study, the Triglyceride level & VLDL level 
cholesterol values are significantly higher in RA patients.(p<0.05) . In our 
study HDL cholesterol values are significantly lower in RA patients. (p < 
0.0001). In our study rheumatoid arthritis patients showed, on average, 1% 
higher total cholesterol ( p>0.05), 18% lower HDL (p<0.05) & 27% higher 
triglyceride than matched controls (p≤0.05). Nineteen RA patients had an  
elevated  triglyceride  level (>150) . 
                                 In  Dijkmans B.A.C.95 et al’s study on dyslipidemia in 
Rheumatoid arthritis, blood samples of patients who later developed 
rheumatoid arthritis showed, on average, 4% higher total cholesterol, 9% 
lower HDL, 17% higher triglyceride and 6% higher apo B levels than 
matched controls (p≤0.05). 
 
 
                                         Adrienne Davis et al87 compared patients who had RA 
without carotid plaque & those with plaque and found that the latter were 
older at the time of the study; were older at onset of disease; had higher 
serum total cholesterol, low density lipoprotein cholesterol, and baseline 
homocysteine levels and higher systolic blood pressure; and were more often 
hypertensive. Most of the patients who participated in our study were taking 
steroids. Corticosteroids can contribute to a type 2b hyperlipidaemia. The   
triglyceride   level ,   LDL  and  HDL  values  may  often  rise  with  
prednisolone  treatment.10   However several other studies  have  been unable  
to demonstrate any association between cardiovascular mortality  and the use 
of corticosteroids. A recent study reported a  small  or  no  increase  in  TC  
levels  during  long-term  administration  of corticosteroids 16.     
                                In our study, the  LDL / HDL ratio is significantly higher 
in RA patients.  The  Total Cholesterol / HDL ratio is also significantly 
higher in RA patients.  George Steiner97 et al showed that Early RA patients 
exhibited mild  higher baseline serum levels of TC, LDL-C, nonHDL-C, 
triglycerides and apoB. Importantly, the serum HDL-C and apoA-I levels 
were significantly lower compared to controls. As a consequence the 
atherogenic ratio of TC/HDL-C as well as that of LDL-C/HDL-C was 
significantly higher in ERA patients compared to controls. 
                        
 
 
                                 In our study total cholesterol and LDL cholesterol is 
slightly higher in rheumatoid arthritis patients, but it did not attain statistical 
significance. Non – HDL cholesterol values were significantly higher in RA 
patients. Low high-density lipoprotein cholesterol (HDL-C<40) was seen in 
53.8% of (23/42) patients. These results were comparable to the results 
obtained in a study conducted by V. Hadda101 et al in which Low high-
density lipoprotein cholesterol (HDL-C) was the commonest abnormality 
seen in 36.1% of (34/96) patients. Disease activity scores (DAS-28) were 
measured at baseline and on a follow-up visit after 3 months and they were 
4.9 (1.02) and 4.4 (0.9), respectively (P = 0.003). With a decline in disease 
activity, a rising trend was observed for all lipids, statistically significant only 
for HDL.                                   
                                      Athanasios N Georgiadis99 et al showed that RA 
patients exhibited higher serum levels of total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C) and triglycerides, whereas their serum high-
density lipoprotein cholesterol (HDL-C) levels were significantly lower 
compared to controls. As a consequence, the atherogenic ratio of TC/HDL-C 
as well as that of LDL-C/HDL-C was significantly higher in ERA patients 
compared to controls. After treatment, a significant reduction of the 
atherogenic ratio of TC/HDL-C as well as that of LDL-C/ HDL-C was 
observed, a phenomenon primarily due to the increase of serum HDL-C 
 
 
levels. These changes were inversely correlated with laboratory changes, 
especially CRP and ESR. 
                             In a similar analysis elsewhere, Dijkmans95 et al 
showed in his study that RA patients exhibited higher serum levels of total 
cholesterol, LDL cholesterol and triglycerides, whereas their serum HDL 
cholesterol levels were significantly lower compared to controls. After 
treatment, a significant reduction of the atherogenic ratio of total cholesterol / 
HDL cholesterol as well as that of LDL cholesterol / HDL cholesterol was 
observed, a phenomenon primarily due to the increase of serum HDL 
cholesterol levels.                              
                                       Some of the studies also report an apparent reduction 
in total cholesterol. This apparent reduction of total cholesterol may result 
from reduced synthesis, increased clearance via the scavenger receptor 
pathway or increased oxidation triggered by the inflammatory process. 
Alternatively the presence of circulating autoantibodies to VLDL and LDL in 
active RA may be responsible. These may also have pre-atherogenic effects 
on the vascular wall by forming immune complexes.98 
                                       Lakatos J, Hárságyi A94 et al in their study measured 
the levels of total cholesterol, HDL, low density (LDL) cholesterol, and 
triglycerides in sera of patients with rheumatoid arthritis and in healthy 
controls. In patients with rheumatoid arthritis (26 men and 103 women), the 
 
 
HDL cholesterol and triglycerides were lower (p less than 0.001) compared 
to the values observed in controls (625 men and 749 women). Similar 
patterns were seen when results of age and sex matched controls were 
compared to the results of patients suffering from rheumatoid arthritis. 
                                         A PubMed literature search was undertaken for 
studies published between 1990 and May 2007, using the search terms 
“rheumatoid arthritis” AND “lipid” OR “lipoprotein,” and including all 
relevant drug treatment terms for glucocorticoids, disease-modifying 
antirheumatic drugs, and biologics. The results showed that patients with RA 
face an increased risk of developing premature cardiovascular disease and 
limited ability to modify risk factors, eg, through exercise. RA is associated 
with an abnormal lipoprotein pattern, principally low levels of high density 
lipoprotein (HDL) cholesterol. Most treatments for RA tend to improve the 
atherogenic index (total/HDL cholesterol ratio), with more evidence for 
biologics in this regard. The improvement in the lipoprotein profile in RA 
appears to be associated with suppression of inflammation. 
                                              The CIMT more than upper limit was seen in 
(13/42 ) RA patients (30.9%) in our study. Only 4 controls (10%) had CIMT 
above the upper limit.  The upper limit of CIMT in our study was 0.72 cms. 
Values of mean CCA IMT above mean + 2 SD of the control group were 
 
 
defined as abnormal IMT. This  Criteria was taken from the study  mentioned 
by  Sundeep grover etal100 . In our study, of the 13 RA patients with CIMT > 
7.2mm , SIX patients had LDL/HDL > 4 and SEVEN patients had TOTAL 
CHO/HDL > 5, and ELEVEN ( 85% ) patients had HDL level <40 mg/dl.  
                                       Indians are also at increased risk of developing early 
and severe atherosclerotic coronary artery disease. Sundeep Grover100etal , 
Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical 
Sciences, Lucknow conducted a study in which Common carotid IMT (CCA 
IMT) was measured at the level of carotid bifurcation along with fasting lipid 
profile in 57 RA patients and 45 age and sex matched controls.  Nineteen RA 
patients (33.3%) and 2 controls (4.44%) had abnormal IMT values. RA 
patients had significantly increased mean CCA IMT (0.558 ± 0.137 mm) as 
compared to controls (0.416 ± 0.002 mm; p < 0.0001). Age ≥ 42 years, 
duration of disease ≥ 6 years, and tender joint count ≥ 5 predicted increased 
risk of having abnormal CCA IMT in a logistic regression analysis.                                     
                                       Carotti M89 et al showed in their study that the  
carotid IMT were significantly higher (p=0.0009) in RA patients (0.83 +/- 
0.23) compared with controls (0.66 +/- 0.22). In RA patients common carotid 
IMT was significantly correlated with serum total cholesterol (p=0.0008), 
low-density lipoprotein cholesterol (p=0.006), triglycerides (p=0.042), age 
 
 
(p=0.031) and disease duration (p=0.019). No significant correlation was 
found with clinical and laboratory parameters reflecting disease activity.   
                                         In our study,  the  CIMT is significantly higher in 
RA patients. (0.68 ± 0.08 vs 0.58 ± 0.07, p value = 0.03). In a similar study 
conducted by Ozgur Ciftcia et al, thirty RA patients (22 women; mean age 
43.7 ± 9.0) and 52 healthy volunteers (38  women; mean age 45.3 ± 5.4) were 
included and in carotid Doppler study,  cIMT values were significantly 
increased in RA patients.(0.6 ± 0.1 vs. 0.5 ± 0.1, P < 0.05).                    
                                 In our study,  CIMT was measured by ultrasonography 
in 42 non-diabetic, normotensive,  RA patients and 40 matched healthy 
controls [age 40.2 (6.9) vs 41.7 (8.1) years].  Gorica G. Ristić et al did a study 
to evaluate the extent of subclinical atherosclerosis in patients with RA and 
low cardiovascular risk by measuring intima-media thickness (IMT) of the 
carotid arteries and to determine factors associated with increased IMT.  
CIMT was measured by ultrasonography in 42 non-diabetic, normotensive, 
female RA patients and 32 matched healthy controls [age 45.3 (10.0) vs 45.2 
(9.8) years] at common carotid arteries (CCAs), carotid bifurcation (BF) and 
internal carotid arteries (ICAs), bilaterally. Mean and maximal (max) IMTs 
were calculated from three measurements at each site. 
 
 
                                    RA patients had increased IMT (mm) in comparison 
with controls [CCAmax: 0.764 (0.148) vs 0.703 (0.100); CCAmean: 0.671 
(0.119) vs 0.621 (0.085); BFmax: 1.055 (0.184) vs 0.941 (0.161); BFmean: 0.889 
(0.168) vs 0.804 (0.124); ICAmax: 0.683 (0.108) vs 0.613 (0.093); ICAmean: 
0.577 (0.101) vs 0.535 (0.076)]. Parameters associated with IMT in RA 
patients were (correlation at x/6 measurement sites): age (6/6), BMI (2/6), 
smoking (2/6), RF concentration (2/6), sedimentation rate (1/6) and duration 
of MTX + chloroquine therapy (4/6; inverse correlation).    
                                  Multivariate regression analysis revealed that RA is an 
independent risk factor for increased IMT. Factors correlating with IMT in 
the controls were: age (6/6), BMI (3/6), total cholesterol (5/6), low-density 
lipoprotein cholesterol (3/6), total/high-density lipoprotein cholesterol (2/6), 
triglycerides (1/6) and glycaemia (4/6).   
                                   Alper  M. van Sijl et al conducted a Meta – Analysis in 
which a systematic literature search and meta-analysis were performed to 
evaluate cIMT difference between RA and controls.  From 22 studies, cIMT 
data were available from 1384 RA patients and 1147 controls. In 17 of the 
studies, RA patients had a statistically significantly greater cIMT. The overall 
mean cIMT difference was 0.09 mm (95%CI: 0.07-0.11 mm). 
 
 
                                    In our study,  RA patients with more than 5 years 
disease duration have a higher atherogenic index and higher CIMT than those 
with less than 5 years of illness.  cIMT had previously been found to be 
increased in patients with long standing RA as shown by del Rincon104 et al. 
He showed that  those with long duration (> 20 years) had a higher cIMT 
compared with patients of the same age but shorter disease duration (< 7 
years). 
                                    Pascal N. Tyrrell105  et al recently did  a systematic 
review and meta-analysis to examine whether rheumatic disease is associated 
with an increased  CIMT  (increasingly used as a surrogate marker for 
atherosclerosis) when compared with healthy control subjects.  A total of 68 
controlled comparisons from 60 different studies were reviewed: 25 (37%) on 
RA,  24 (35%) on SLE, 6 (9%) on systemic sclerosis, and 13 (19%) on other 
rheumatic diseases. The estimated summary effect size between control and 
study subject CIMT measurement comparisons, with preexisting 
cardiovascular disease excluded, was 0.64 (95% CI, 0.46 to 0.82). This 
represented an overall absolute mean difference of 0.06 mm (95% CI, 0.05 to 
0.06 mm). Preexisting cardiovascular disease, rheumatic disease type, and 
disease duration contributed to heterogeneity.   
 
 
                                    Carlos Gonzalez-Juanatey106 et al did a study to  
establish whether carotid intima-media wall thickness (IMT) may be a good 
predictor for the development of cardiovascular (CV) events in patients with 
rheumatoid arthritis (RA). A series of 47 RA patients who at the time of 
recruitment did not have traditional CV risk factors or CV disease were 
assessed by carotid ultrasonography. Carotid IMT was measured in the right 
CCA. Then, a prospective assessment of the CV outcome was performed 
over a 5-year period.   
                                   Carotid IMT was greater in RA patients who over the 
extended follow-up experienced CV events (1.01 ± 0.16 mm), compared with 
the remaining RA patients who did not have CV complications (0.74 ± 0.12 
mm) (P < 0.001).  None of the patients with carotid IMT less than 0.77 mm 
had CV events. However, 6 of the 10 patients with carotid IMT greater than 
0.91 mm experienced CV events (p value for the trend <0.001). Carotid IMT 
yielded a high predictive power for the development of CV events over the 5-
year follow-up period. The results from this study support the use of carotid 
ultrasonography as a predictor of CV events in RA. 
 
 
 
 
 
 
 
 
 
LIMITATIONS OF THE STUDY 
                            Most of the patients who participated in the study were 
on steroids and a few were also on DMARD/immunosuppressants. The 
dosage and frequency of intake of drugs were highly variable among the 
participants. This may have influenced the values in the study as their 
modifying effect on lipid profile and CIMT were not taken into account 
during the period of study.                                                                                             
 
                                   
 
 
 
 
 
                                        SUMMARY 
1. Cardiovascular manifestations are frequent in rheumatoid arthritis (RA) and 
significantly contribute to morbidity and mortality in this disorder. Premature 
atherosclerosis is responsible for these complications, as supported by 
autopsy studies. 
2. A total  of   42 [ FEMALE (F)-33 ;  MALE (M)-9 ] RA  patients participated 
in our study. 
3. There is no significant difference in Total Cholesterol and LDL values 
between RA patients and the control population. 
4.  In our study, (19/42) RA patients  had  an  elevated  triglyceride  level.  
5. As many as 23  RA patients had a low HDL level ( <40 ).   
6. Among the control group - [ TOTAL – 40 (M-10/F-30) controls ] - only 5 
had an elevated triglyceride level & only 9 had a  low HDL level. 
7. Among RA group , 24 patients(57% ) had LDL / HDL ratio >3 when        
compared to only 5% in the control group.  
8. Ten(25%) RA patients had LDL/HDL ratio > 4. 
9. Interestingly, 21 RA patients (50% ) had Total Chol/ HDL ratio> 5  
while only 5% of control population had such an atherogenic profile.  
10. Thirteen (31%) RA patients had CIMT > 7.2 mm while only 4 in the          
control group  had elevated values. 
 
 
11.  There is no significant difference  between rheumatoid factor positive  
  and rheumatoid factor negative patients.  
12.  The mean duration of illness in the study is  5.1 years. 
13.  CIMT is higher in all age groups in RA patients when compared to  
  control population. 
14. The CIMT is significantly high in RA patients. 
15.  The  LDL / HDL ratio is significantly high in RA patients. 
16. The  Total Cholesterol / HDL ratio is also significantly higher in RA    
patients. 
17. There is no relation between DAS score and atherogenic index or  
  CIMT values. 
18. RA patients with more than 5 years disease duration have a higher  
  atherogenic index and higher CIMT. 
19.  The HDL cholesterol values are significantly low and the TOTAL   
CHO/HDL & LDL/HDL ratios are significantly high in RA patients. 
20. The LDL / HDL ratio & The Total Cholesterol / HDL ratio are 
   significantly high in CRP POSITIVE patients. 
21.   HDL cholesterol values are significantly low in CRP positive patients. 
22.  RA is an independent risk factor for increased  CIMT. 
 
 
 
 
  
                                      CONCLUSION 
• Forty two RA patients attending Rheumatology clinic, Govt. Rajaji 
Hospital, Madurai, and 40 controls who satisfied the inclusion and 
exclusion criteria were selected for the study.  
• RA patients have an atherogenic lipid profile and a significant increase 
in Carotid Intima Media Thickness. 
• There is no significant difference in Total Cholesterol and LDL  
           values between RA patients and the control population. 
• The Triglyceride level , VLDL level &  non – HDL cholesterol level  
 
           is significantly high in RA patients. 
 
• HDL cholesterol values are significantly low in RA patients. 
 
• The  LDL/ HDL  ratio is significantly higher in RA patients. 
 
• The  Total Cholesterol / HDL ratio is also significantly high 
 
           in RA patients. 
 
• RA patients with more than 5 years disease duration have a higher  
 
           atherogenic index and higher CIMT values. 
 
• There is no relation between DAS score and atherogenic index  
 
           or  CIMT values. 
 
• There is no significant difference  between rheumatoid factor  
 
           positive  and rheumatoid factor negative patients.  
 
 
 
• The LDL / HDL ratio & The Total Cholesterol / HDL ratio is 
 
           significantly higher in CRP POSITIVE patients. HDL cholesterol  
            
           values  are significantly low in CRP positive patients.  
 
• The CIMT is significantly high in RA patients compared to controls. 
 
• Thirteen (31%) RA patients had abnormal CIMT. 
 
• RA is an independent risk factor for increased  CIMT. 
 
• Lipid levels should be monitored and managed in patients with RA to 
minimize the long-term risk of cardiovascular disease. More research 
is needed to quantify the relationship between systemic inflammation 
and lipoprotein levels and to determine the impact of specific 
lipoprotein particles, eg, small dense low-density lipoprotein and sub 
fractions of HDL on long-term risk. Control of inflammation may have 
an effect on modifying cardiovascular risk. 
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PROFORMA 
 
NAME :       AGE:            SEX:          
 
PHONE NO :           OP NO:       
 
ADDRESS: 
 
HISTORY: 
Arthritis   : 
Nodules   : 
Raynaud’s phenomenon : 
Sicca symptoms  : 
Syncope /chest pain /palpitation 
Wheeze / dyspnoea / weakness. 
 
 
Arthritis   +  /  -      +         - 
 
MCP 
PIP 
DIP                                                                                               
Wrist                                                Morning stiffness 
Elbow                                                  Nodules 
Shoulder        Raynaud’s 
 
TM         Eye—Red ,,Dry 
SC 
    Rash 
Hip 
Knee          Ulcers 
Ankle        Gangrene 
ST 
    Numbness/ paraesthesia 
MT 
Spine        Nail fold infarct 
 
 
Duration of illness 
 
DAS 28 SCORE 
 
Past history 
 
TB,   Hepatitis,    DM,  CAD,  HT,    Hypothyroidism  , IHD. 
Personal history 
 
Smoking , CAD, use of ocp,  steroids 
 
Occupation 
 
 
Family history: 
 
DM/HT/CAD/Hypercholesterolemia. 
 
General  examination 
 
Pallor  Icterus  Cyanosis  Clubbing  Lymphadenopathy  Oedema 
 
PR      BP      BMI 
 
Markers of atherosclerosis 
 
CAROTID BRUIT   + - 
 
 
Systemic examination: 
 
RS:                                                                                      CVS: 
 
 
 
 
ABDOMEN:                                                                       CNS: 
 
 
 
 
 
 
INVESTIGATIONS: 
 
 
Hematology:   Hb  TC   DC 
 
 
Sugar               Urea            Creatinine          TSH  LFT 
 
 
LIPIDS            Total Cholesterol          TGL          LDL          HDL        VLDL 
 
Tot Cho / HDL             LDL/HDL 
 
 
ESR             ECG             RF        CRP    X-RAYS 
 
 
CAROTID DOPPLER STUDY 
 
 CIMT (MM)     :  RT  :  LT  :  MEAN  : 
 
 
Treatment    History 
Steroids 
 
Methotrexate 
 
Hydroxy chloroquine 
 
Other immune agents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS AND ACRONYMS 
• CIMT  -  Carotid Intima Media Thickness 
• BP       -  Blood Pressure 
• M         -  Male 
• F          -  Female 
• TC       -  Total cholesterol 
• CRP     -  C reactive protein 
• ESR     -  Erythrocyte sedimentation rate 
• RA       -  Rheumatoid arthritis 
• RF        -  Rheumatoid factor 
• DAS     -  Disease activity scale 
• BMI     -  Body mass index 
• TGL     -  Triglyceride 
• VLDL   -  Very low density lipoprotein 
• LDL      -  Low density lipoprotein 
• HDL     -  High density lipoprotein 
• TSH     -  Thyroid stimulating hormone 
• CAD    -  Coronary artery disease 
 
 
 
MASTER CHART ABBREVIATIONS 
Age AGE 
Sex SEX 
DUR DURATION OF ILLNESS  IN YEARS 
PRV PREVIOUS TREATMENT 
RA f RHEUMATOID FACTOR 
CRP C-Reactive Protein 
ESR Erythrocyte Sedimentation Rate 
Das28 Disease Activity Scale 
TGL TRIGLYCERIDE LEVEL 
VLDL VLDL CHOLESTEROL 
LDL LDL CHOLESTEROL 
HDL HDL CHOLESTEROL 
TOT.C TOTAL CHOLESTEROL 
NO.HC NON HDL CHOLESTEROL 
LD/HD LDL/HDL RATIO 
TC/HD TOTAL CHOLESTEROL/HDLCHOLESTEROL 
RBS Random Blood Sugar 
HB Hemoglobin 
TSH Thyroid stimulating hormone 
Urea UREA 
CR CREATININE 
BP BLOOD PRESSURE 
BMI Body Mass Index 
CIMT Carotid Intima Media Thickness 
CrB Carotid Bruit 
ECG Electrocardiogram 
NEG NEGATIVE 
POS POSITIVE 
 
 
 
  
 
 
 
Figure 1- showing how to measure CIMT 
 
 
 
 
 
 
Figure 2   MEASURING INTIMA MEDIA THICKNESS IN RIGHT CCA 
 
FIG 1A-   AGE GROUP DISTRIBUTION IN STUDY AND CONTROL GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1B    SEX DISTRIBUTION IN BOTH GROUPS 
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FIGURE 1C         DURATION OF ILLNESS 
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FIGURE  1G 
DAS SCORE DISTRIBUTION AMONG STUDY POPULATION 
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FIGURE 2A    BMI & LIPID PROFILE IN STUDY GROUP AND CONTROL 
GROUP 
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FIGURE  2C- 
 
CAROTID INTIMA MEDIA THICKNESS IN STUDY & CONTROL GROUP 
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FIGURE 2B -CIMT  AND ATHEROGENIC INDEX IN STUDY GROUP 
& 
CONTROL GROUP 
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FIGURE 3A 
AGE & CAROTID INTIMA MEDIA THICKNESS IN STUDY  & CONTROLS 
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FIG 3 B 
CIMT , LIPID PROFILE  & ATHEROGENIC INDEX 
IN STUDY GROUP &  CONTROL GROUP 
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FIGURE 3C  - ATHEROGENIC INDEX AND CAROTID INTIMA 
MEDIAL THICKNESS IN RELATION TO DAS SCORE 
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FIGURE 3D      DISEASE DURATION AND ATHEROGENIC INDEX AND CIMT 
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FIG4A – 
COMPARISON BETWEEN CRP POSITIVE & NEGATIVE CASES 
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FIGURE 4 B - 
     COMPARISON BETWEEN CRP POSITIVE AND CRP NEGATIVE CASES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LDL /HDL
TC /HDL
C IMT  (mm)
DAS  S C OR E
3.33
2.31
5.5
4.3
7.1
6.8
4.38 4.24
C R P  +VE C R P  ‐VE
 
 
 
 
 
 
 
 
 
 
 
COMPARISON OF RHEUMATOID FACTOR POSITIVE & NEGATIVE CASES 
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